{"title":"The prevalence of anxiety symptoms and disorders among ophthalmic disease patients.","authors":"Zulvikar Syambani Ulhaq, Gita Vita Soraya, Nadia Artha Dewi, Lely Retno Wulandari","doi":"10.1177/25158414221090100","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Progressive and irreversible vision loss has been shown to place a patient at risk of mental health problems such as anxiety. However, the reported prevalence of anxiety symptoms and disorders among eye disease patients vary across studies. Thus, this study aims to clarify the estimated prevalence of anxiety symptoms and disorders among ophthalmic disease patients.</p><p><strong>Methods: </strong>Relevant studies on the prevalence of anxiety symptoms and disorders among eye disease patients were collected through international databases, PubMed, Scopus, and Web of Science. A random-effects model was used to determine the pooled prevalence of anxiety symptoms and disorders among ophthalmic disease patients.</p><p><strong>Results: </strong>The 95 included studies yielded a pooled prevalence of 31.2% patients with anxiety symptoms and 19.0% with anxiety disorders among subjects with ophthalmic disease. Pediatric patients were more anxious (58.6%) than adults (29%). Anxiety symptoms were most prevalent in uveitis (53.5%), followed by dry eye disease (DED, 37.2%), retinitis pigmentosa (RP, 36.5%), diabetic retinopathy (DR, 31.3%), glaucoma (30.7%), myopia (24.7%), age-related macular degeneration (AMD, 21.6%), and cataract (21.2%) patients. Anxiety disorders were most prevalent in thyroid eye disease (TED, 28.9%), followed by glaucoma (22.2%) and DED (11.4%). When compared with healthy controls, there was a twofold increase on the prevalence of anxiety symptoms (OR = 1.912, 95% CI 1.463-2.5, <i>p</i> < 0.001) and anxiety disorders (OR = 2.281, 95% CI 1.168-4.454, <i>p</i> = 0.016).</p><p><strong>Conclusion: </strong>Anxiety symptoms and disorders are common problems associated with ophthalmic disease patients. Thus, comprehensive and appropriate treatments are necessary for treating anxiety symptoms and disorders among ophthalmic disease patients.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"14 ","pages":"25158414221090100"},"PeriodicalIF":2.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/81/10.1177_25158414221090100.PMC9021519.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414221090100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 4
Abstract
Background: Progressive and irreversible vision loss has been shown to place a patient at risk of mental health problems such as anxiety. However, the reported prevalence of anxiety symptoms and disorders among eye disease patients vary across studies. Thus, this study aims to clarify the estimated prevalence of anxiety symptoms and disorders among ophthalmic disease patients.
Methods: Relevant studies on the prevalence of anxiety symptoms and disorders among eye disease patients were collected through international databases, PubMed, Scopus, and Web of Science. A random-effects model was used to determine the pooled prevalence of anxiety symptoms and disorders among ophthalmic disease patients.
Results: The 95 included studies yielded a pooled prevalence of 31.2% patients with anxiety symptoms and 19.0% with anxiety disorders among subjects with ophthalmic disease. Pediatric patients were more anxious (58.6%) than adults (29%). Anxiety symptoms were most prevalent in uveitis (53.5%), followed by dry eye disease (DED, 37.2%), retinitis pigmentosa (RP, 36.5%), diabetic retinopathy (DR, 31.3%), glaucoma (30.7%), myopia (24.7%), age-related macular degeneration (AMD, 21.6%), and cataract (21.2%) patients. Anxiety disorders were most prevalent in thyroid eye disease (TED, 28.9%), followed by glaucoma (22.2%) and DED (11.4%). When compared with healthy controls, there was a twofold increase on the prevalence of anxiety symptoms (OR = 1.912, 95% CI 1.463-2.5, p < 0.001) and anxiety disorders (OR = 2.281, 95% CI 1.168-4.454, p = 0.016).
Conclusion: Anxiety symptoms and disorders are common problems associated with ophthalmic disease patients. Thus, comprehensive and appropriate treatments are necessary for treating anxiety symptoms and disorders among ophthalmic disease patients.
背景:进行性和不可逆转的视力丧失已被证明会使患者面临焦虑等心理健康问题的风险。然而,在不同的研究中,眼病患者中焦虑症状和疾病的患病率有所不同。因此,本研究旨在厘清眼病患者焦虑症状和障碍的估计患病率。方法:通过国际数据库、PubMed、Scopus和Web of Science收集眼病患者焦虑症状和障碍患病率的相关研究。采用随机效应模型确定眼病患者焦虑症状和障碍的总患病率。结果:纳入的95项研究显示,眼部疾病患者中有焦虑症状的患者占31.2%,有焦虑障碍的患者占19.0%。儿科患者的焦虑程度(58.6%)高于成人(29%)。焦虑症状在葡萄膜炎患者中最为普遍(53.5%),其次是干眼病(DED, 37.2%)、色素性视网膜炎(RP, 36.5%)、糖尿病性视网膜病变(DR, 31.3%)、青光眼(30.7%)、近视(24.7%)、年龄相关性黄斑变性(AMD, 21.6%)和白内障(21.2%)。焦虑障碍在甲状腺眼病中最常见(TED, 28.9%),其次是青光眼(22.2%)和DED(11.4%)。与健康对照组相比,焦虑症状的患病率增加了两倍(OR = 1.912, 95% CI 1.463-2.5, p p = 0.016)。结论:焦虑症状和障碍是眼病患者的常见问题。因此,对眼病患者的焦虑症状和障碍进行全面、适当的治疗是必要的。